The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / ‘Nothing but NET[osis]’: RheumMadness 2022 Anti-NET Antibodies Scouting Report

‘Nothing but NET[osis]’: RheumMadness 2022 Anti-NET Antibodies Scouting Report

February 8, 2022 • By The UNC Rheumatology Fellowship Program: Leah Bettner, MD; Shruti Chandramouli, MD; Christopher Overton, MD; Astia Allenzara, MD; Michael Cunningham, MD; & Luis Palomino, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Editor’s note: RheumMadness is the place for everyone crazy about rheumatology to connect, collaborate, compete and learn together. During RheumMadness, rheumatology concepts represent teams that compete against each other in a tournament, much like basketball teams do in the NCAA’s March Madness tournament. In a series for The Rheumatologist, readers will get a chance to read the scouting reports for each concept team. These reports are written by rheumatology fellows from 13 programs throughout the U.S.

You Might Also Like
  • Conversation: RheumMadness 2022 Reproductive Health Guide Scouting Report
  • A Unique Breed: RheumMadness 2022 Dalmatian Urate Scouting Report
  • An Oral Targeted Therapy: RheumMadness 2022 Pim Kinases Scouting Report
Explore This Issue
May 2022

Don’t forget to submit your RheumMadness 2022 bracket by March 25. The more your picks match those of our Blue Ribbon Panel of rheumatologists, the more points you get. Learn more about the panel and how the brackets work online.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Connect with RheumMadness by subscribing to the podcast and joining the conversation on Twitter, #RheumMadness. Learn more on the RheumMadness website.

Region: Cells

Team: Anti-NET Antibodies

Activated neutrophils produce neutrophil extracellular traps (NETs), networks of DNA and proteins via a process called NETosis, to trap and kill pathogens. NETs are implicated in a multitude of autoimmune disease processes and may be involved in thrombophilic disease states, such as antiphospholipid syndrome (APS), cancer and COVID-19 infection.

In the base article for this RheumMadness team, researchers suggest that in primary APS antiphospholipid antibodies engage the neutrophil surface by circumventing normal homeostatic mechanisms to trigger the release of NETs. Patients with APS were found to have higher levels of circulating NETs than healthy controls. Activity of circulating anti-NET antibodies was measured in 76 patients with primary APS, 23 patients with SLE without antiphospholipid antibodies (aPL), 11 patients with a history of unprovoked venous thromboembolism (VTE) without aPL and 44 healthy controls.1

The researchers found patients with primary APS have markedly elevated levels of circulating anti-NET IgG and IgM antibodies compared with healthy controls. Patients with SLE without positive aPL also had elevated anti-NET IgG and IgM antibodies. Those with a history of unprovoked VTE without aPL had higher levels of IgM anti-NET antibodies than healthy controls. Anti-NET antibody activity in primary APS did not correlate with levels of traditional aPL (e.g., anti-B2GP1 and lupus anticoagulant) and was relatively stable over time. Further, anti-NET antibodies—particularly IgG—impaired the ability of patient sera to degrade NETs, and levels of anti-NET IgM were inversely correlated with complement C4 levels, suggesting activation of the complement cascade. The researchers hypothesized NETs can directly activate complement, which may promote coagulation through effects on tissue factor and platelets. Lastly, both IgG and IgM anti-NET antibodies were associated with clinical manifestations of APS (e.g., unproved venous thrombosis and arterial thrombosis), and high IgG levels were associated with recurrent venous thrombosis.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE
ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 4 | Single Page

Filed Under: Conditions, Research Reviews Tagged With: anti-NET antibodies, Antiphospholipid Antibody Syndrome (APS), APS, cells, NETosis, neutrophil extracellular traps, RheumMadnessIssue: May 2022

You Might Also Like:
  • Conversation: RheumMadness 2022 Reproductive Health Guide Scouting Report
  • A Unique Breed: RheumMadness 2022 Dalmatian Urate Scouting Report
  • An Oral Targeted Therapy: RheumMadness 2022 Pim Kinases Scouting Report
  • Get the Picture: RheumMadness 2022 PET-CT in Large Vessel Vasculitis Scouting Report

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)